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Abstract—This article investigates two cases of priority setting to
explore how, in addition to technical considerations, ethical and political
factors shape the allocation of health resources. First, we discuss how
Thai authorities adjudicated a coverage decision for HLA-B*1502
screening, which meets the national cost-effectiveness threshold for
only some of the conditions it can detect. Second, we consider
England’s Cancer Drugs Fund to investigate the interplay of technical
decision making and political reality. Our findings suggest four
concluding observations for policy makers and others considering
priority-setting processes. First, we observe that different methods can
produce conflicting recommendations, which makes priority setting
very complex. Second, we suggest that robust processes for generating
and weighing political, ethical, and technical evidence are essential
because there is no absolute standard by which resource allocation
decisions can be made. Third, priority setting is inherently political, and
improving its technical and ethical validity means constructing political
importance for these other factors. Fourth, we argue that transparency in
the trade-offs required to set priorities is important ethically and can
help build support politically.
INTRODUCTION
Priority setting in health involves decisions about who gets
what, when, and how, to paraphrase Lasswell’s definition of
politics.1 It is a contested process because the demand for
services is unlimited and resources are finite. Priorities have
to be set that reflect health needs, economic resources, pro-
fessional and societal values, and political considerations.
This formulation follows the categories of technical, ethical,
and political developed by Roberts et al. for the analysis of
health reform.2 Setting priorities is a difficult task that
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concerns policy makers whether they are looking to intro-
duce efficiency savings or policies to advance universal
health coverage (UHC). Priority setting includes highly
technical processes such as the calculation of quality-
adjusted life years (QALYs), incremental cost effective-
ness ratios (ICERs), and other health economic measures.
Priority-setting processes are not purely technical,
though—they give rise to ethical dilemmas and are sub-
ject to political influences, as well.3 However, it is
unclear how these factors might be accounted for institu-
tionally, especially in low- or middle-income countries
considering how to build priority-setting institutions. Ethi-
cal frameworks developed in high-income countries over
the last decades represent attempts to systematically guide
decision making, and these would seem to be a sound
starting point. In contrast, how best to account for politi-
cal factors in priority-setting processes remains a more
elusive endeavor and a relatively underresearched area,
despite contributions on specific cases and methods of
analysis.4-7
We address the following question: What can we learn
about managing the priority-setting process from two cases
in which ethical and political factors shaped the ultimate
decisions on how to allocate health resources? We begin by
providing a brief overview of the literature on the technical,
ethical, and political aspects of priority setting. This is fol-
lowed by an introduction to the two cases discussed in this
article, namely, the screening for HLA-B*1502 as a bio-
marker for severe hypersensitivity induced by carbamazepine
in Thailand and the establishment of the Cancer Drugs Fund
(CDF) in England. Finally, we discuss the two case studies
and offer four lessons for policy makers and others consider-
ing priority-setting processes.
TECHNICAL APPROACHES TO PRIORITY
SETTING IN HEALTH
Priority setting refers “[. . .] to the allocation of resources in
health care both in terms of the relative priority to be
attached to different demands and needs and to decisions that
are made not to fund treatment.”8 In many cases, such deci-
sions are informed by technical approaches, such as cost-
effectiveness analyses or evidence-based clinical guidelines.
Among many examples, Thailand and England have estab-
lished institutional bodies with a mandate to conduct (or con-
tract for) such technical analyses to inform decision-making
on what is included in or excluded from the health benefit
basket. In this trend toward decision making based on tech-
nology appraisals, “[. . .] pharmaceutical products are the
main—but by no means the only—subjects of such
appraisals.”9
“Technical” approaches or “technical” institutions are
referred to as such because they are concerned primarily
with bringing technical analysis to bear on policy decisions,
although we recognize that both reflect many factors, includ-
ing political and ethical ones. For instance, the decision to
establish technical bodies is made through political pro-
cesses, whether parliamentary or executive, and some are
explicitly charged with considering social values.10 Consid-
ering many forms of evidence and analysis is important
because very commonly data are insufficient or evidence is
difficult to interpret.11 Further, the interpretation of technical
evidence is partly a social process: the same randomized con-
trolled trial evidence is interpreted differently depending on
different national paradigms.12
THE ETHICS OF PRIORITY SETTING
Priority setting concerns the distribution of health benefits
and burdens in society. That this is also an ethical issue was
recognized early among ethicists who, inspired by theories
of distributive justice, explored how to meet health needs
fairly.13-15 Others emphasized the motivation for health
maximization.16,17
Ethical Principles for Priority Setting
Despite some disagreement between different theoretical
frameworks, some consensus has emerged during the last
decades over what kinds of ethical considerations are rel-
evant (Box 1). First, there is general agreement that prior-
ity setting should be impartial; that is, unprejudiced and
unbiased. Every citizen should be treated with equal
respect and dignity. Second, the formal principle of
equality—treating equals as equals—always applies. This
formal principle can take two forms: people who are
equal in all relevant respects should be treated equally
(horizontal equity), and people who are unequal in the
relevant respects should be treated unequally (vertical
equity). The formal principle of equality is a standard
against which any clinical or political decision could be
measured. If two patient groups are equal on all relevant
criteria, they are treated unequally if one group is given
priority over the other.18 This often happens in practice
but is nevertheless ethically unacceptable. Third, there is
broad agreement that priority setting should aim at both
fair distribution and health maximization.19
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Ethical Criteria for Priority Setting
There is, among ethical theories of priority setting, overlap-
ping consensus on a set of three relevant criteria (Box 1). If
some service or policy is documented as effective, the mag-
nitude of the health effect is relevant under both a distribu-
tive and a maximizing principle. One widely accepted
measure of effectiveness is healthy life years (using quality-
adjusted life years or disability-adjusted life years). The cost
of the service in question is also always relevant. Decision
makers need to know whether an alternative use of resources
could lead to a more fair or more efficient distribution. A
third criterion, severity of disease—or, simply, health with-
out the service—is seen as necessary and relevant only under
the principle of fair distribution. This is relevant because
decision makers need information about who is worse off if a
service is not given priority. The health maximization princi-
ple does not consider who is worse off; instead, only aggre-
gate benefit matters. However, many ethicists agree that both
fair distribution and health maximization matter and there-
fore that all three criteria are relevant.19,20
It is also possible, and indeed obligatory, to take non-
health benefits and burdens into consideration when setting
priorities. In the context of low- and middle-income coun-
tries, a fourth relevant criterion, financial risk protection, has
been widely discussed and accepted.21
There is also some agreement among ethical theories
about irrelevant criteria for priority setting. Even if contra-
vened in practice, it is not considered acceptable to treat peo-
ple differently according to their gender, race, ethnicity,
religion, sexual orientation, or social status. However, there
is still substantial disagreement about the relevance of con-
tested criteria, including age, responsibility for own health,
area of living, and personal income.a
Making Ethical Judgments
Evaluating priority setting against ethical principles requires
information, analysis, judgment, and the use of public reason.
In the case of so-called horizontal equity, this can be quite
straightforward (see Box 1).
Though making ethical judgments using the outlined cri-
teria can be straightforward in some cases, it is more com-
plex in others. Reasonable people agree on much but may
disagree about when people are unequal in the relevant sense
or about which criteria are relevant and how they should be
interpreted, applied, and weighted.22 Some therefore argue
that substantive evaluation of priority-setting decisions
should be replaced by assessments according to criteria for
fair and legitimate process.23 Others argue that both process
and substantive judgments are important, a viewpoint with
which the present authors agree.24 Accountability for reason-
ableness is one widely accepted framework that sets out con-
ditions for legitimate process.25 The core idea is that reasons
for priority-setting decisions should be publicly available.
This means that those who provide and pay for services
should make the range of services they offer public and that
the reasons for inclusion or exclusion are made clear to all
key stakeholders, assuming that all seek reasonable justifica-
tions for such decisions. More specifically, accountability for
reasonableness suggests four conditions that should be met:
publicity, relevance, revision and appeals, and regulation.
Priority setting should be publicly justified with reference to
relevant reasons and evidence. A fair process should be
inclusive with broad stakeholder involvement and mecha-
nisms for critical assessment and revision. The process itself
should be institutionalized so that all key decisions meet
these conditions. If satisfied, these four conditions can con-
nect decisions about priority setting to broader educative and
deliberative democratic processes.26
In summary, priority setting affects the distribution of
health benefits and burdens in society. Even if there is some
disagreement between ethical theories about specific issues,
there is wide support for and no discernable disagreement in
the relevant ethics literature that priority setting should be
impartial, treat people as equals, and follow from clearly rel-
evant and agreed criteria. Most theories also promote fair dis-
tribution and health maximization as key principles. Both
substantive and procedural criteria can be used to evaluate
and criticize priority-setting decisions.
THE POLITICS OF PRIORITY SETTING
In addition to the technical approaches and ethical frame-
works, the literature on the political aspects of priority setting
provides analytical lenses that help examine political forces.
Against the background of one prominent definition of poli-
tics as the study of who gets what, when, and how,1 priority
setting can be viewed as fundamentally political because of
its distributional consequences. This view is supported by
many studies examining the political nature of priority set-
ting and health reform 2,3,5-7,27-32 and the evaluation of the
Oregon Health Plan.29
In what ways is priority setting fundamentally political?
First and foremost it arises as a policy response to the univer-
sal challenge of building and sustaining high-quality health
care systems that are constrained by national fiscal space but
charged with satisfying demand that often expands and is
very hard to reduce. Second, it is political because policy
Kieslich et al.: Factors in Priority Setting 53
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makers must balance competing needs and interests between
different groups and stakeholders at societal and government
levels. For example, economic interests might demand poli-
cies that strengthen the pharmaceutical sector as a provider
of employment opportunities and an investor in research and
development, but these policies may be at odds with the
individual and societal interest in limiting drug expenditures
and increasing access.33
Priority-setting outcomes that are viewed negatively by
certain groups are often opposed through political processes,
whether in the public eye or behind the scenes. Commonly,
advocacy groups have contested decisions from the National
Institute for Health and Care Excellence (NICE) and lobbied
English policy makers by framing issues in emotional and
ethical terms. For example, in 2008 NICE decided not to rec-
ommend kidney cancer medicines it had found to be cost
ineffective; this was contested with the slogan that kidney
cancer patients “deserved the right to life.”34
Third, priority setting involves many actors,2,3 at many
different levels of decision making.35 This implies that even
the most transparently designed and technically sound prior-
ity-setting processes are inputs into larger political processes
that involve complex relationships between actors and reflect
the contested political economy of health. Even priority-set-
ting institutions designed to moderate political pressures by
basing decision making on economic analyses and transpar-
ent processes consist of complex political processes involv-
ing many stakeholders who may hold different values and
worldviews. Finally, like other policy areas, health policy is
subject to the results of election cycles, changing government
priorities, and economic trends.
In the triad of technical, ethical, and political judgments
that comprise priority setting,2 the technical and ethical
aspects appear easier to navigate as methods and frameworks
to aid decision makers have been developed. By comparison,
the question how to navigate the political forces of priority
setting appears more challenging because such forces can
have greater power than even the strongest institutions, are
subject to internal and external influences that can be difficult
to disentangle or predict, and can change very quickly. How-
ever, existing tools and analyses from political science and
other disciplines 2,4-7,27-32 can help understand, manage, and
navigate these forces.
METHODS
This article examines two cases of priority setting in which
ethical and political factors were reflected explicitly in the
final decisions. That is, the decision problems were not solv-
able by reference to technical approaches alone and ethical
and political judgments were made in addition. We explore
the possible lessons that can be learned but do not suggest
that they are generalizable to all contexts. Nevertheless, we
contend that these cases are a helpful introduction, for policy
Box 1 Ethical Aspects of Priority Setting
Key principles
1. Priority setting should be impartial, unprejudiced, and
unbiased
2. The formal principle of equal treatment
- People who are equal in all relevant respects should be
treated equally (horizontal equity)1, and
- People who are unequal in the relevant respects should be
treated unequally (vertical equity)
3. Priority setting should aim at both fair distribution and
health maximization
Relevant criteria for priority setting
- Magnitude of health effect
- Alternative cost
- Health without the service in question (severity of disease)
- Financial risk protection
Irrelevant criteria
- Gender
- Race
- Ethnicity
- Religion
- Sexual orientation
- Social status
Contested criteria
- Age
- Responsibility for own health
- Area of living
- Personal income
1
If two patient groups are equal on all relevant criteria – they have the same
health if not treated, the expected outcomes are the same, and service costs
are the same – they are treated unequally if one group is given higher prior-
ity, say because of ethnicity. In cases of vertical equity, when people are
unequal in a relevant sense, the judgments become more complex. But even
here, the overlapping consensus offers advice. For example, if we consider a
given case, where two groups have the same health status without the ser-
vice, and the same expected outcomes, but alternative costs differ widely –
most ethical theories of distributive justice in health will accept that the
more cost-effective service is given priority. This is so because the two
groups differ in one relevant sense and in no other. The two groups are
treated differently for the right reason. Similarly, if two groups are similar
with respect to cost-effectiveness of the service they need, but differ in health
without this service, say the first group has multiple sclerosis and average
healthy life expectancy is lower than for a group with, say, influenza, vertical
equity implies that the former service should have priority.
54 Health Systems & Reform, Vol. 2 (2016), No. 1
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makers and others, to the roles of ethical and political consid-
erations in priority setting.
The cases in this study are examples of priority setting
under the national health benefit plans of Thailand and Eng-
land. The screening for HLA-B*1502 as a biomarker for
severe hypersensitivity induced by carbamazepine in Thai-
land was selected because it is an example of how ethical
considerations can be incorporated into the priority-setting
process. It exemplifies a challenge that frequently arises in
technology appraisals of interventions: how to make a deci-
sion when the technical evidence suggests different clinical
and cost-effectiveness outcomes for different patient groups.
Such scenarios raise ethical questions of whether to treat the
groups the same or differently.
The CDF in England was selected because it exemplifies
priority setting by political processes, which, in the view of
some analysts,36 undermined important technical and ethical
considerations. The future of the CDF is still unfolding, but
given the controversy the creation of the CDF has caused
and the issues that it raises, the case illustrates how public
policy concerns such as media pressure and policy priorities
such as addressing low cancer survival rates may lead to
decisions that cannot be explained by reference to technical
or ethical considerations alone.
CASE STUDY: SCREENING FOR HLA-B*1502 AS A
BIOMARKER FOR SEVERE HYPERSENSITIVITY
INDUCED BY CARBAMAZEPINE IN THAILAND
Background
In Thailand, 67 million citizens are eligible for essential
health care subsidized by three government schemes,
namely, the Civil Servant Medical Benefit Scheme, the
Social Security Scheme, and the Universal Coverage Scheme
(UCS; covers three-fourths of the population). The National
List of Essential Medicines has been adopted by these
schemes as their pharmaceutical benefits package.37 By this,
access to all items on the list is warranted for people with
clinical conditions as indicated for particular drugs. For most
indications, drugs of first choice and alternatives are listed
according to the safety, clinical effectiveness, and cost-effec-
tiveness; physicians are expected to prescribe first-line drugs
unless the patient does not respond well or cannot tolerate
side effects. However, because all drugs have at least some
undesirable effects and many are potentially hazardous, pol-
icy makers and prescribers face the continuous and difficult
challenge of how to weigh the expected benefits versus the
probability of harm.
This case study focuses on an essential drug, carbamaze-
pine, which is recommended as first-line treatment for epi-
lepsy and neuropathic pain.38 The drug may induce severe
adverse reactions including Steven-Johnson syndrome (SJS)
and toxic epidermal necrosis (TEN) in some patients.
Although SJS and TEN are life-threatening, the incidence of
such reactions induced by carbamazepine in Thailand is only
0.27% in neuropathic pain patients and 0.33% in epilepsy
cases.39 Therefore, beginning the treatment of epilepsy and
neuropathic pain with more expensive but safer second-line
alternatives is regarded as inefficient practice.
An alternative to carbamazepine is sodium valproate for
epilepsy and gabapentin for neuropathic pain. Drug expendi-
ture per case per year of carbamazepine is 2,550 Thai Baht
(THB),b sodium valproate is 13,930 THB, and gabapentin is
11,740 THB. In addition, lifetime treatment cost per case
(including drug cost, treatment cost for its adverse reactions,
and direct non-medical care costs) when prescribing carba-
mazepine is 19,000 THB for treatment of neuropathic
pain and 42,000 THB for epilepsy, sodium valproate
84,000 THB, and gabapentin 36,000 THB. The probability
of severe adverse effects induced by sodium valproate and
gabapentin is approximately 0.04%.c Because the publicly
funded coverage policies are guided by three primary consid-
erations—that is, population-level health outcomes, value for
money, and financial implications at the societal level40—
carbamazepine is listed as the medicine of first choice for the
two indications in the benefit package and clinical practice
guidelines.41,42
Recent development in biogenetics has resulted in an
invention to predict the likelihood of drug-induced hypersen-
sitivity in patients. Because the presence of a human leuko-
cyte antigen, HLA-B*1502, is strongly associated with
carbamazepine-induced SJS and TEN, screening for such an
antigenic allele can help identify individuals with high
risk.43 In the case of a positive test result, carbamazepine’s
alternative will be prescribed. In 2013, the HLA-B*1502
screening test was proposed to be subsidized by the UCS.
As requested by the UCS authority, the National Health
Security Office (NHSO), an assessment of the proposed
intervention was conducted by an independent health tech-
nology assessment (HTA) institution, the Health Intervention
and Technology Assessment Program. The findings sug-
gested that screening for HLA-B*1502 in Thailand is cost-
effective when carbamazepine is prescribed to patients with
neuropathic pain and cost ineffective in epilepsy treat-
ment.d,44 Because cost-effectiveness is a major criterion for
coverage decisions, the screening test should have been pro-
vided to neuropathic patients only. However, because the
UCS considered ethical reasons, including treating similar
Kieslich et al.: Factors in Priority Setting 55
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cases in the same way and avoiding inconsistency in pre-
scribing guidelines for carbamazepine to the two groups of
patients,45 the UCS subsidizes the screening in epilepsy cases
as well. The decision makers’ argument was that the risk and
severity of carbamazepine-induced adverse reactions are
identical in both groups of patients.
Discussion
Although key stakeholders such as health providers, patient organ-
izations, and health products industry continue to request that the
NHSO issue explicit criteria for its benefit coverage, the policy
authority keeps it flexible. This does not mean that UCS decisions
are made without direction. In 2009, the NHSO instigated a pro-
gram to ensure systematic, transparent, participatory, evidence-
based technology appraisal, whereby value for money and budget
implication are major concerns.40 In practice, however, the deci-
sions on particular interventions do not always conform to the two
criteria, because other elements such as financial risks for the poor
(if life-saving interventions are not covered in the UCS), program
feasibility, and equity in access to related services across subpopu-
lationsmay be consideredmore important.46
The Subcommittee for UCS Benefit Package Development
agreed to cover the screening test for patients with neuropathic
pain and epilepsy because this policy conformed to the equity
principle and helped avoid inconsistency in treatment provision to
the two groups of beneficiaries.44 The decision suggests a view
that although subsidizing the test in epileptic patients is not a cost-
effective option, selectivelywithholding such a clinically effective
intervention, which reduces the chance of severe side effects, is
ethically unjustified. From an ethical perspective, omitting the
screening test can be seen as leaving the patients to face the pre-
ventable life-threatening drug reactions and offering inequitable
access to the life-saving intervention. The Subcommittee’s deci-
sion indicates a high regard for the key principle of equal treat-
ment (horizontal equity). Patients have the same risk of side
effects and should be given equal changes to have themprevented.
If, on the other hand, the principle of vertical equity applies, the
two groups are equal in most respects, except that one group is
more costly to screen and treat than the other. According to the
principles and criteria outlined in Box 1, cost is a relevant differ-
ence and the two groups need not be treated equally. Therefore, in
this case, reasonable people may disagree and fair processes may
be helpful to resolve the issue.
This case study also highlights the importance of articulat-
ing reasons in a transparent way when making decisions in
health priority setting. In the UCS, where explicit coverage
decision criteria are lacking, decision makers need to provide
the public with the reasons and justifications for covering or
rejecting each intervention. The UCS’s accountability
involves accountability for allocating public resources to
ensure equitable access to standard health services among
Thai citizens, and efficiency and financial sustainability of
the health system must be secured.47 Because there may be
legitimate disagreement about ethical choices, policy author-
ities need to make the decision-making process transparent
and participatory.48 In particular, when cost-ineffective inter-
ventions are adopted, the rationale and related information
including perspectives of stakeholders involved in the delib-
eration should be accessible in public domain. In our analy-
sis, the UCS model of health priority setting, which is not
strictly based on value for money, is accepted among stake-
holders because efficiency is not the only goal of universal
health coverage.49,50
CASE STUDY: THE CANCER DRUGS FUND
Background
In England, NICE makes recommendations on whether new
pharmaceutical products should be made available in routine
practice of the National Health Service (NHS). NICE uses
ICERs to express the additional costs of new treatments in
comparison to current alternatives and examines them in
relation to the clinical benefits.51 The clinical benefits are
expressed in QALYs (quality-adjusted life years).e The
threshold for new drugs to be recommended on the NHS is
an ICER of £20,000–£30,000 per QALY.51 In addition to the
use of these clinical and cost-effectiveness measures, NICE
has developed guidelines for making social value judgments
and for considering so-called end-of-life criteria.10,52 Drugs
that are above the QALY threshold may be recommended if
considerations such as social value judgments or end-of-life
criteria apply. A consideration of end-of-life criteria is
included in the majority of appraisals of cancer drugs even
though not all of them meet the criteria.f Positive recommen-
dations by NICE are binding, meaning that the treatments in
question have to be made available on the NHS.
The CDF in England was established by the Conserva-
tive–Liberal coalition government in 2010. It was set up as a
ring-fenced fund—meaning that the resources allocated to
the CDF cannot be spent on other services—through which
cancer patients can access cancer medicines that had not yet
been evaluated by NICE or that had not been recommended
by NICE. The CDF started with a budget of £200 million,
which has since been increased on several occasions, first to
£280 million and most recently to £340 million for 2015/
2016 because of overspending in the past years.54 To date,
the total cost of the CDF was £968 million and the overspend
in budget for the year 2014–2015 was 48%.55 In addition,
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74,380 patients have received access to drugs via the CDF
since 2010.55
The CDF was intended as a temporary measure until a
system of value-based pricing was established. This was to
be an approach in which the NHS, with support of organiza-
tions like NICE, assessed the value of a drug and in which
the price was to reflect this value. However, this new
approach never materialized. The leading organization of the
NHS, NHS England, has recently published proposals that
would align the CDF more with NICE. Although the public
consultation is ongoing, the CDF could become a managed
access scheme as of April 2016, with NICE holding a major
role in deciding which drugs will be available via the
CDF.56,57
Discussion
The creation of the CDF caused some bewilderment in the
research and health care communities.36 Critics of the CDF
argue that it does not address the challenge of low cancer sur-
vival rates because it does not address the problem of waiting
times for diagnostics and there is not a convincing case for
why cancer patients should be privileged over other patient
groups by having access to a ring-fenced drugs fund. Observ-
ers have also suggested that the CDF undermines the work of
NICE,58 leading to two parallel decision-making processes
for new cancer drugs. The CDF has also been described as
playing into the hands of powerful lobbies such as the phar-
maceutical industry59 and the cancer charities.
The above criticisms reflect the technical, ethical, and
political aspects of priority setting. The argument that the
CDF does not address the length of waiting times for
diagnostic procedures reflects the view that more techni-
cal forms of evidence should inform priority setting.
From an ethical perspective, one might argue that the
CDF violates the principle of impartiality—because it is
partial to the needs and concerns of cancer patients
only—and raises questions with regard to the principles
of fair distribution of resources and health maximization
for all patient groups. On the other hand, by taking
account of disease severity, ethical frameworks may allow
for an ethical justification for the establishment of the
CDF. However, for such a justification to be valid, the
same ethical considerations should apply to other patients
groups where severity of disease or health loss is substan-
tial, as in the case of multiple sclerosis, for example.
Though the CDF raises important ethical and technical
questions, the CDF exemplifies the influence of the political
realm. The lower cancer survival rates compared to other
European countries were framed as the main reason for the
creation of the CDF. Moreover, the political decision to con-
tinue the CDF was framed as a matter of saving and extend-
ing lives, a frame that is difficult to challenge in the public
domain. Upon announcing the extension of the CDF in 2013,
Prime Minister David Cameron said, “When I became Prime
Minister three years ago, many patients with rare cancers
were being denied lifesaving treatments. That is why we cre-
ated the Cancer Drugs Fund, it is why we are extending it.
[. . .]”60
NICE had already responded to public and political pres-
sure by introducing end-of-life criteria. These criteria permit
a higher cost-effectiveness threshold when drugs provide a
valuable extension of life at the end of life, even if this exten-
sion may be marginal in some cases,53 but even then some
cancer drugs were not considered sufficiently cost-effective.
The Coalition prioritized funding for cancer patients over
other patients based on what they perceived as politically
necessary. Faced with recurring negative headlines about
NICE denying effective treatments to patients and England’s
low cancer survival rates, policy makers are prone to go for
politically opportune options to be seen to be “doing some-
thing.”g As one media outlet put it: “[. . .] the fund had the
political benefit of defusing damaging arguments that have
arisen when officials have denied access to expensive cancer
treatment [. . .] on cost–benefit grounds.”62
Observers have argued that in establishing the CDF, the
Coalition questioned the current process of priority setting,
putting the future of NICE on the political agenda.58 How-
ever, this does not seem to be the case because the govern-
ment continues to provide strong support for the institution,
indeed securing its future by enshrining its existence in the
new NHS legislation.63 This suggests that the creation of the
CDF is another indication that in health priority setting, tech-
nical, ethical, and political judgments need to be considered
alongside each other.
Given the existence of NICE as an HTA organization in
England, the creation of the CDF can be interpreted as an
expression of political forces that could not be fully managed
by even a very robust HTA agency. The political salience of
the future of the CDF is highlighted by the previously out-
lined changes proposed for the fund.56,57 Despite these
maneuverings, the challenge of denying access to cancer
drugs when they are available elsewhere has still not been
resolved. The proposed new approach is being watched
closely by all stakeholders. As such, the CDF illustrates that
political factors such as the need to address public opinion,
unsatisfactory performance in key health areas, and the
appeal of offering a compelling public narrative can lead to
policy choices that may diverge from technical evidence and
ethical judgments.
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CONCLUDING OBSERVATIONS
In this article we considered two cases of priority setting in
hopes of illuminating some of the challenges that can arise
when different analytic methods suggest different courses of
action. Although an examination of only two cases cannot
provide definitive evidence on the broader questions we
raise, we nonetheless believe that our investigation provides
a reasonable basis for advancing four observations about the
priority-setting process. We furnish these observations in the
hopes that they will be useful to policy makers considering
how to strengthen or extend priority-setting processes.
1. Different Methods Can Produce Different Recom-
mendations: The cases discussed in this article show
that technical, ethical, and political considerations are
all very important and may each recommend divergent
courses of action. Similarly, formal priority-setting
institutions may generate recommendations that are
contested through broader political processes. The
cases we present here show some of the complexity of
priority setting and illustrate some of the diverse influ-
ences that shape decisions.
2. Robust Processes Are Essential: There is no absolute
standard for setting priorities or weighting different
types of evidence when they conflict, meaning that the
most appropriate choice depends on a robust process
for making decisions. In our opinion, these observa-
tions highlight the need for mechanisms to generate
and consider each type of evidence and the need for
mechanisms that can adjudicate differences between
them; for instance, by creating agreement on an order
of importance for political, ethical, and technical fac-
tors or by establishing institutions or processes to do so.
3. Priority Setting is Inherently Political: We began this
article by observing that priority setting concerns who
gets what, which is one definition of politics. We pro-
pose that if priority setting is inherently political, then
its outcomes necessarily reflect political influences. In
this light, political factors are the easiest to incorporate
in priority setting because they are a function of exist-
ing political processes. By contrast, neither ethical nor
technical factors are included by definition. The inclu-
sion of technical and ethical factors can be challenging
because it requires the construction of political visibil-
ity for these factors, which is not necessarily present in
any given setting. We hypothesize that ethical factors
have some intuitive political weight because they
depend on values and judgments that are widely shared.
We further speculate that technical factors can be more
challenging to assert politically because typically they
depend on calculations accessible only to experts. In
this light, we propose that priority setting can be con-
sidered usefully as the construction of processes to give
political weight to ethical and technical factors.
4. Transparency Can Help Build Support: Even the
term “priority setting” conveys a sense of the ration-
ing conflict that underpins the need to choose some
interventions or actions at the expense of some
others. The cases we examined suggest that transpar-
ency about the trade-offs of different choices is an
important ethical requirement and a potentially valu-
able means of building political support because it
promotes participation and clarifies the implications
of different choices.
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NOTES
[a] For a more detailed discussion of these criteria, see
Norheim et al.20
[b] A purchasing power parity (PPP) dollar is 17.505 THB
in 2011.
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[c] Based on experts’ estimation because local data in Thai-
land are not available.
[d] In Thailand, the cost-effectiveness threshold, endorsed
by the UCS manager, is 160,000 THB per QALY gain;
the incremental cost-effectiveness ratio when HLA-B*
screening test is provided to patients with neuropathic
pain and epilepsy is 130,000 THB per QALY gain and
220,000 THB per QALY gain, respectively. The differ-
ence in value for money of introducing the screening
test between the two indications is mainly driven by the
cost of carbamazepine’s alternatives: gabapentin is
11,740 THB per year and sodium valproate is
13,930 THB per year. The costs of alternative drugs are
included in the cost-effectiveness analysis of the screen-
ing test, because providing screening intervention
alone, without replacing carbamazepine with alternative
drugs, cannot yield the desirable health outcome.
[e] For a detailed explanation of NICE’s methodology, see
NICE.51
[f] A detailed discussion of the end-of-life criteria is
beyond the scope of this article. For more details, see
NICE’s guidelines. 53
[g] The attractiveness of the CDF policy to politicians is
further underlined by the Labour Party’s 2015 election
campaign pledge to maintain the CDF, albeit in an
adjusted format, in case it won the general election.61
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